Milestone Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Its Initial Public Offering

Print More

MONTREAL and CHARLOTTE, N.C., May 14, 2019 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of

Comments are closed.